Individualized dosing regimens specific to the patient, infection, bacteria, and antibiotic can optimize outcome. Integration of pharmacokinetic and pharmacodynamic data, called dual individualization, can be accomplished through the use of AUIe. AUIC dosing has been shown to predict bacteriological outcomes, hasten clinical outcomes, reduce the emergence of resistance, and be cost-effective. MPC dosing has been shown to predict the emergence of resistant submutants. AUIC and MPC information can provide guidance as to when low doses can be used, and when higher concentrations are required. This strategy can ensure efficacy, minimize toxicity, reduce the opportunity for resistance to occur, and save money. REFERENCES I. Paladino JA. Streamlining antibiotic therapy: clinical application of pharmacokinetic and pharmacodynamic principles. J Osteopath Med 1991; 5: 16-25. 2. Liss RH, Batchelor FR. Economic evaluations of antibiotic use and resistance - a perspective: report of task force 6. Rev Infect Dis 1987; 9 (suppI3): S297-312. 3. Holmberg SO, Solomon SL, Blake PA. Health and economic impacts of antimicrobial resistance. Rev Infect Dis 1987; 9: 1065-78. 4. Sanders cc. Mechanisms responsible for cross-resistance and dichotomous resistance among the quinolones. Clin Infect Dis 2001; 32(Suppl I ): S 1-8. 5. Ballow CH, Schentag 11. Trends in antibiotic utilization and bacterial resistance: report of the NNRSG. Diagn Microbiol Infect Dis. 1992; 15(suppl):37S-42S. 6. Rice LB, Eckstein EC, DeVente J, Shlaes OM. Ceftazidime-resistant Klebsiella pneumoniae isolates recovered at the Cleveland Department of Veterans Affairs Medical Center. Clin Infect Dis 1996; 23: 118-24

This volume is focused on the development of vaccines which generate immune effectors capable of blocking mucosal entry or peripheral pathogen spread. A critical first step in the design of mucosal vaccines is the selection of administration route. Not all mucosal immunization routes are created equally when it comes to eliciting immune responses in multiple body compartments. This subject and situations when a mucosal route may not be required for vaccine delivery are reviewed here with an emphasis on the sublingual immunization route, which may offer a safer alternative to the nasal route for induction of broadly disseminated immune responses. External host defenses that inhibit entry of microorganisms at mucosal surfaces also pose obstacles to the efficient internalization of mucosally-applied vaccines. Transcutaneous immunization with appropriate adjuvants and permeation enhancers can induce mucosal immune responses and may be advantageous for bypassing these luminal barriers. Other chapters describe strategies for enhancing uptake of mucosal vaccines, for instance through targeted delivery to antigen-sampling M cells, construction of virus-like particles which mimic natural pathogens, addition of mucoadhesives or formulation as nanoparticles. Topics include edible vaccines as well as plant-based production of subunit or particulate vaccines that could be administered by any route. Dry powder vaccines that could be insufflated or directly applied to mucosal surfaces may be particularly ideal for mass vaccination in developing countries. The manufacture, stability and efficacy of powder formulations is comprehensively reviewed. We conclude with chapters on two of the greatest challenges facing mucosal vaccine development: human immunodeficiency virus and bioterrorist agents. This monograph highlights progress and information that should prove invaluable for the development of contemporary vaccines that prevent infection by these and other mucosal pathogens.

Contents:
1. Positive Selection of B Cell Repertoire, Idiotype Networks and Immunological Memory 2. The Utility of Immunoglobulins Fusions in DNA Immunisation 3. Constraints on the Hydropathicity and Sequence Composition of HCDR3 are Conserved Across Evolution 4. Molecular Aspects of Anti-Polysaccharide Antibody Responses 5. Molecular Farming Antibodies in Plants: From Antibody Engineering to Antibody Production

The complement system plays a major role in the host's defence against infections and in immune complex diseases. Although it is known to consist of a number of serum and membrane proteins that interact through a cascade, there is still a poor understanding of the exact nature of the components and their complex interaction. Many of the biological consequences of complement activation also await elucidation. This fully revised edition of "Complement in Health and Disease" provides an up-to-date account of how the system works and its effects on the host. Key topics covered include the history, phylogeny and evolution of the system; genetics and biochemistry; deficiency states and infection; immune complex diseases; complement and angioedema; anaphylatoxins; and diseases of the nervous system. The book is valuable both for those wanting an introduction to this complex area of immunology as well as those requiring a more detailed update on developments in specific topics.

Tumor necrosis factor (TNF) superfamily is a rapidly growing family of cytokines that interacts with a corresponding superfamily of receptors. Ligand-receptor interactions of this superfamily are involved in numerous biological processes ranging from hematopoiesis to pleiotropic cellular responses, including activation, proliferation, differentiation, and apoptosis. The particular response depends on the receptor the cell type, and the concurrent signals received by the cell. Worldwide interest in the TNF field surged dramatically early in 1984 with the cloning and defining of the profound cellular effects of the first member of this family, TNFa. Subsequently, the major influence of TNFa on the development and functioning of the immune system was established. Today, over 20 human TNF ligands and their more than 30 corresponding receptors have been identified. Few receptors still remain orphans. What has emerged over the years is that most TNF ligands bind to one distinct receptor and some of the TNF ligands are able to bind to multiple TNF receptors, explaining to some extent the apparent disparity in the number of TNF receptors and ligands. Yet, in spite of some redundancy in TNF ligand/receptor interactions, it is clear that in vivo spatial, temporal, and indeed cell- and tissue-specific expression of both ligands and their receptors are important factors in determining the precise nature of cellular physiological and pathological processes they control.

TNF superfamily has been the most highly investigated area of basic medical research for over two decades. These investigations have benefited from the enormous growth in our understanding of the principal functions of theimmune system and the explosion in the knowledge involved in regulation of normal and pathological immune response. In addition, much has been learned about the molecular mechanisms of programmed cell death and the escape of tumor cells from apoptotic demise and from discovery of the key role played by TNF ligands in this process. As the functioning of these superfamily members is very complex, understanding TNF ligands and their receptor biology requires a mA(c)lange of research activities in many different disciplines including organ development, molecular biology, experimental pathology, and immunology. As a consequence of intensive studies in multiple areas over many years, much has been learned. A key role of members of this superfamily in normal functioning of the immune system, autoimmunity, and other fundamental cellular process by which tumor cells develop has been established. Many novel mechanisms involving TNF superfamily members in the disease development process have been defined, and a unified concept and new perspectives have also emerged. For example, abrasions in the innate immune system, so far not considered critical in autoimmunity, have found increasing attention, and TNF-directed and not antigen directed therapy has emerged as the most impressive therapeutic advance in managing autoimmunity in humans. These findings provide a foundation for novel drug design efforts that are poised to utilize newly acquired knowledge. Several of these strategies have already materialized into successful therapeutics such as use of TNF for cancers and anti-TNFa antibodies and TNFR-Fc for autoimmune diseases, and many have advanced to human clinical trials, while many more are stillbeing tested in preclinical settings.

As in other rapidly evolving fields, these advances are not necessarily congruent and are often difficult to organize into a cogent whole. The aim of Therapeutic Targets of the TNF Superfamily is to make readily available the major research important in the exploitation of this family for developing therapeutic strategies for human diseases, in a single volume. Under the auspices of Landes Bioscience, I have undertaken the task to concisely consolidate current knowledge of key TNF superfamily members focusing on both basic aspects and their clinical application. In this volume, a number of leading scientists in the field cover many aspects of biology of TNF superfamily members, ranging from the cloning and characterization of TNF ligands and their receptors, through the use of animal models to study their functions in vivo and their exploitation for human therapeutic use. Each chapter also includes relevant background information and provides useful bibliography for a more detailed analysis, making the study of TNF ligands/receptors accessible at all levels of expertise.

Book covers course with topics in infectious diseases in children and is intended for Pediatric Infectious disease clinical researchers, trainees, trainers, and all those who manage the research of children with infections and the children themselves. The conference is being supported by several societies and is sponsored by several pharmaceutical companies, such as Aventis, Baxter, Chiron Vaccines, Wyeth, etc. ToC reflects the scientific program found here: http: //www.oxfordiic.org/#course

Over the past decade, significant progress has been made in the theory and applications of pharmacodynamics of antimicrobial agents. On the basis of pharmacokinetic-pharmacodynamic modeling concepts it has become possible to describe and predict the time course of antimicrobial effects under normal and pathophysiological conditions. The study of pharmacokinetic-pharmacodynamic relationships can be of considerable value in understanding drug action, defining optimal dosing regimens, and in making predictions under new or changing pre-clinical and clinical circumstances. Not surprisingly, pharmacokinetic-pharmacodynamic modeling concepts are increasingly applied in both basic and clinical research as well as in drug development.

The book will be designed as a reference on the application of pharmacokinetic-pharmacodynamic principles for the optimization of antimicrobial therapy, namely pharmacotherapy, and infectious diseases. The reader will be introduced to various aspects of the fundamentals of antimicrobial pharmacodynamics, the integration of pharmacokinetics with pharmacodynamics for all major classes of antibiotics, and the translation of in vitro and animal model data to basic research and clinical situations in humans.

This is a review text on medical microbiology and immunology containing approximately 625 board-type review questions on left-hand pages with answers and explanations on facing right-hand pages. It is designed for medical students taking microbiology as well as for those studying for Step 1 of the National Board Exams and is also useful for Step 3 National Boards on infectious diseases or allergy and immunology. The book's main sections cover general and medical microbiology, bacteriology, virology, immunology, and parasitology. The answers summarize relevant information and point out the fault in incorrect answers. Line drawings and figures are used for questions concerning structure of both molecules and organisms and for interpreting graphical results. Authors Reese, Brownell, and Nair, all with the Medical College of Georgia, bring a combined total of some 85 years of medical school teaching experience to their development of the questions and annotated answers for this book.

This authoritative, single-source reference provides comprehensive examinations of the complement system-offering recent findings in basic science on the structure, biology, physiology, and pathophysiology of complement proteins and the latest therapeutic approaches towards the control of complement-mediated diseases. Written by over 40 international experts from North America, Europe, and Asia, The Human Complement System in Health and Disease -describes the molecular architecture of the complement system -details the structure of complement genes -discusses gene organization as well as the topology and chemistry of ligand-binding sites and catalytic centers of complement proteins -analyzes complement organization and activation, including phylogeny and the newly discovered lectin pathway -elucidates the regulation of complement gene expression and the structure and function of bioactive peptides -explicates opsonic and immunoregulatory properties of complement fragments, endothelial responses, and interactions with viruses and bacteria -and more!

The COVID-19 pandemic served as a powerful wake-up call, highlighting our collective need for the effective development and equitable distribution of new vaccines, in addition to widespread administration of existing ones. The current models of production and allocation of vaccines against emerging pathogens, which rely on predominantly market-driven mechanisms, are largely at odds with public health needs. This book is the first to explore the entire arc of vaccine development and distribution, from the decisions about allocation of vaccine R&D money to allocation and administration of vaccines resulting from the R&D process. It explains key concepts and problems in vaccine regulation, intellectual property, technology transfer, and international relations, making complex material accessible to a non-specialist audience. Analyzing the impact of COVID-19, the book also covers several other vaccine races, as well as future directions in vaccine development and allocation.

Session I.- Breast Mucin and Associated Antigens in Diagnosis and Therapy.- Peptide Epitopes in Breast Cancer Mucins.- Does a Novel Form of the Breast Cancer Marker Protein, MUC1, Act as a Receptor Molecule that Modulates Signal Transduction?.- Cancer Metastasis Determined by Carbohydrate-Mediated Cell Adhesion.- Experimental Immunotherapy of Breast Cancer Using Alpha Interferon Conjugated to Monoclonal Antibody Mc5.- Circulating and Tissue Markers in the Longitudinal Management of Breast Cancer Patients.- Session II.- Engineering of Antibodies for Breast Cancer Therapy: Construction of Chimeric and Humanized Versions of the Murine Monoclonal Antibody BrE-3.- Humanization of an Anti-Mucin Antibody for Breast and Ovarian Cancer Therapy.- Towards an Immunotherapy for p185HER2 Overexpressing Tumors.- Session III.- Branching N-Linked Oligosaccharides in Breast Cancer.- Specificity of the IgG Response in Mice and Human Breast Cancer Patients Following Immunization Against Synthetic Sialyl-Tn, an Epitope with Possible Functional Significance in Metastasis.- Vaccination Against Breast Cancer - Studies in an Animal Model.- Anti-Idiotype Antibodies as Potential Therapeutic Agents for Human Breast Cancer.- The Simultaneous Expression of c-erbB-2 Oncoprotein and Laminin Receptor on Primary Breast Tumors has a Predicting Potential Analogous to that of the Lymph Node Status.- Multivariate Prognostic Model for Infiltrating Ductal Carcinoma of the Breast in the Axillary Node-Free Patient.- The Use of Monoclonal Antibody Immunoconjugates in Cancer Therapy.- Radioimmunolocalization of Breast Cancer Using BrE-3 Monoclonal Antibody.- Suppression of Human Anti-Mouse Antibody Response to Murine Monoclonal Antibody L6 by Deoxyspergualin: A Phase I Study.- Overview of Radioimmunotherapy in Advanced Breast Cancer Using 1-131 Chimeric L6.- Contributors.

The genus Chlamydia encompasses a number of species of obligate intracellular bacteria, including important human pathogens like the most common bacterial agent of sexually transmitted disease. This volume reviews current knowledge of chlamydial biology, covering the unusual structure of the bacteria - which alternate between metabolically almost inactive and fast-dividing forms. It also discusses the ways in which Chlamydia manipulates the host cytoskeleton and subverts the host cell's defence, and illustrates how genomics have begun to uncover the diversity and complexity of chlamydial strains that look very similar but may cause distinct forms of disease. Further, it describes how techniques are now finally being established that can genetically modify Chlamydia, and discusses why such modification is still very difficult and what progress we can expect. Lastly, it presents our current understanding of chlamydial disease: what do we know about chronic infections, what are the mechanisms of inflammatory damage, and what are the prospects of a vaccine? Written be specialists in these various areas, the book is a valuable work of reference for students and scientists with an interest in the molecular, cellular and immunobiology of these fascinating bacteria.

This book draws together important facts, in particular areas of vascular biology, and allows the generation of hypotheses and principles that unite an area and define newer horizons. It is designed for scientists and physicians interested in immunology, inflammation and cardiovascular diseases.

Morphology.- The Pineal Gland of Mammals: Some Open Morphological Questions.- Demonstration of Nerve Fibers Immunoreactive to met-Enkephalin, leu-Enkephalin, and ss-Endorphin in the Bovine Pineal Gland.- Comparative Studies of VIP-, PHI-, and NPY-Immunoreactive Nerve Fibers in the Pineal Gland of the Sheep.- Biochemistry.- Pharmacological Regulation of Receptor-Mediated Indoleamine Metabolism in the Mammalian Pineal Gland.- Regulation of Melatonin Synthesis and Release: Paracrine Relationships in Mammalian Pineal Gland.- New Aspects Concerning the Regulation of Pineal Indoleamine Metabolism: Implications for Neuroimmunology.- The Use of Perifusion Technique in the Research of Pineal Neuroendocrinology. The Role of Different Neurotransmitters in the Regulation of Pineal Melatonin Secretion.- Interferon-? Modulates Indoleamine Metabolism in Rat Pineal Gland in Organ Culture.- Melatonin Receptors.- High-affinity Melatonin Receptors in Mammals: Localization, G-Protein Coupling and Signal Transduction.- Melatonin Receptors in Discrete Areas of Rat and Hamster Brain: Modulation by Melatonin, Testosterone and the Photoperiod.- Melatonin Binding Sites in the Nervous and Immune Systems.- 2-?125I? Iodomelatonin Binding in Normal and Neoplastic Tissues.- Melatonin in the gastrointestinal tract.- Biochemical Characteristics of Melatonin Receptors in Different Organs and Translation of Hormonal Signal in the Nucleus.- Physiology.- Annual Changes in the Daily Pattern of Melatonin Synthesis and Release.- Integration of Environmental Signals by the Pineal Gland and its Significance for Seasonality in Small Mammals.- Opioid Involvement in Melatonin Action.- Effect of Melatonin on NADH-Oxidoreductase Activity and Cyclic Nucleotide Levels in Rat Adrenals.- Temporal Profile of Superoxide Dismutase Activity in the Pineal Gland and the Liver of Rats.- Pineal-Harderian Gland Interactions: Morphological and Physiological Evidences for an Endocrine Function of the Syrian Hamster Harderian Gland.- Melatonin Enhances GABA-Mediated Effects when Administered by Micropressure Ejection in Single Unit Neuronal Recordings.- Immunology.- Action of Melatonin on Immune System.- Opioids in Immune Cells.- Spleen Morphology and Lymphoproliferative Activity in Short Photoperiod Exposed Hamsters.- Melatonin Reconstitutes the Decreased CFU-S Content in the Bone Marrow of Hypothalamus - Lesioned Mice.- Oncology.- Melatonin Action on Oncogenesis.- The Effects of Melatonin and Melatonin Analogues on the P388, DLD-1 and MCF-7 Tumor Cell Lines.- Is there a Role for the Pineal Gland in Neoplastic Growth?.- Clinical Studies.- Melatonin, Immunity and Cancer in Humans.- Evidence for a Sex-Specific Facilitatory Effect of Melatonin on Prolactin Secretion. Is Pineal-Prolactin Interaction Relevant to the Clinical Course of Breast Cancer?.- Pineal-Interleukin 2 Interactions and their Possible Importance in the Pathogenesis of Immune Dysfunctions in Cancer.- Significance of Melatonin to Chronobiology: Immunological Correlations.- Circadian Profile of Serum Melatonin in Cushing's Syndrome and Acromegaly.- Urinary 6-Sulfatoxymelatonin Excretion in Breast Cancer Patients and Control Subjects.- Interindividuel Differences in the Responses of Serum and Salivary Melatonin to Light.- Contributors.

Examines how conspiracy theories and related forms of misinformation and disinformation about the Covid-19 pandemic have circulated widely around the world. Commissioned by recognised experts on area studies and conspiracy theories, making use of the existing COMPACT (Comparative Analysis of Conspiracy Theories) network run by Butter and Knight. Presents case studies on how Covid conspiracism has played out, using a range of methods from a variety of disciplinary perspectives.

Macrophages are a key component of the innate immune system and play an integral role in host defense and homeostasis. On one hand, these cells contribute to host defence by triggering inflammation, displaying microbicidal/tumoricidal properties, regulating the activation of adaptive immunity and promoting resolution of inflammation. On the other hand, they contribute to essential trophic functions such as neural patterning, bone morphogenesis and ductal branching in mammary glands. Thus, macrophages are extremely versatile cells that can respond efficiently to tissue micro environmental cues by polarizing to distinct phenotypes, depending on the functions they need to perform. Indeed, functional diversity and plasticity are hallmarks of these cells.

Macrophages may also play a detrimental role. An overwhelming body of literature has indicated their crucial role in pathogenesis. The list includes sepsis, cancer, metabolic syndrome, immunodeficiency, auto-immune disease-virtually impacting every major pathology that we know. These observations have suggested macrophages and their related molecules as potential targets in therapeutic applications. Available evidence proclaims macrophages as a key player in homeostasis, host defense and disease. Crucial developments in the past few years call for a re-evaluation and update of our understanding of macrophages. The present book is an endeavour that attempts provide state-of-the art knowledge of these cells in health and disease.

The COVID-19 pandemic served as a powerful wake-up call, highlighting our collective need for the effective development and equitable distribution of new vaccines, in addition to widespread administration of existing ones. The current models of production and allocation of vaccines against emerging pathogens, which rely on predominantly market-driven mechanisms, are largely at odds with public health needs. This book is the first to explore the entire arc of vaccine development and distribution, from the decisions about allocation of vaccine R&D money to allocation and administration of vaccines resulting from the R&D process. It explains key concepts and problems in vaccine regulation, intellectual property, technology transfer, and international relations, making complex material accessible to a non-specialist audience. Analyzing the impact of COVID-19, the book also covers several other vaccine races, as well as future directions in vaccine development and allocation.

Innate and adaptive immunity play important roles in immunosurveillance and tumor destruction. However, increasing evidence suggests that tumor-infiltrating immune cells may have a dual function: inhibiting or promoting tumor growth and progression. Although regulatory T (Treg) cells induce immune tolerance by suppressing host immune responses against self- or non self-antigens, thus playing critical roles in preventing autoimmune diseases, they might inhibit antitumor immunity and promote tumor growth. Recent studies demonstrate that elevated proportions of Treg cells are present in various types of cancers and suppress antitumor immunity. Furthermore, tumor-specific Treg cells can inhibit immune responses only when they are exposed to antigens presented by tumor cells. Therefore, Treg cells at tumor sites have detrimental effects on immunotherapy directed to cancer.

Lupus, a disease of the immune system, can be quite deadly, claiming the lives of thousands of patients yearly. Dr. Daniel J. Wallace is one of the world's leading authorities on this disorder, an eminent clinician who has treated over 3,000 lupus patients, the largest such practice in America. His The Lupus Book, originally published in 1995, immediately established itself as the most readable and helpful book on the disease. Now Dr. Wallace has once again completely revised The Lupus Book, incorporating a wealth of new information. This Sixth Edition discusses new drug information and newly discovered information about the pathology of the diseaseall laid out in user-friendly language that any patient could understand. In particular, Wallace discusses the first drug for lupus to be approved by the FDAbelimumab (Benlysta)as well as other drugs in clinical trials. Readers will also discover fully updated sections on the science of lupus and breakthroughs in research including: genetics, microbiome, and clinical trial methodology. And as in past editions, the book provides absolutely lucid answers to such questions as: What causes lupus? How and where is the body affected? Can a woman with lupus have a baby? And how can one manage this disease? Indeed, Dr. Wallace has distilled his extensive experience, providing the most up-to-date information on causes, prevention, cure, exercise, diet, and many other important topics. There is also a glossary of terms and an appendix of lupus resource materials compiled by Dr. Wallace. Over 1.5 million Americans have lupus. The new Sixth Edition offers these patients and their families an abundance of reliable, information that will help them manage the disease and live a happier life.

A simple, clear, scientifically proven plan to boost metabolic health and help our immunity to the virus Covid-19 by one of the world's most influential cardiologists.

Dr Aseem Malhotra, a leading NHS cardiologist, has led the way in citing obesity, Type 2 diabetes and heart disease as frequent factors in those hospitalised with coronavirus. He shows how they result from poor metabolic health, including an over-dependence on ultra-processed foods, which seriously affects our immune response.

In this life-changing 21 Day Plan he brings us the good news that we can reverse our health and rapidly improve our resilience to infection and disease through just a few simple lifestyle changes - to our diet, how we exercise and sleep, and reduce stress.